SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Passive Stake in Allurion Technologies

Sentiment:

Beneficial Ownership Report Amendment


Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.99% of Allurion Technologies, Inc.'s common stock as of March 31, 2025.

Summary

  • Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Allurion Technologies, Inc.
  • As of March 31, 2025, the Reporting Persons collectively beneficially own 391,643 shares of Allurion Technologies, Inc. Common Stock.
  • This ownership represents 4.99% of the outstanding Common Stock, calculated based on 7,848,566 shares outstanding as of April 25, 2025, as reported in the Issuer's Form S-3 filed on April 30, 2025.
  • Armistice Capital, LLC, acting as the investment manager for Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these securities.
  • Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
  • The Reporting Persons certify that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects.

Positives

  • The filing indicates a passive investment, suggesting no immediate intent by the Reporting Persons to influence or change control of Allurion Technologies, Inc.
  • The investment is held in the ordinary course of business by an established investment manager and its managing member.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

  • Shareholders: Provides transparency regarding a significant passive ownership stake held by an institutional investor and its managing member.

Key Dates

DateDescription
03/31/2025Date of event which requires filing of this statement.
04/25/2025Date as of which 7,848,566 shares of Allurion Technologies, Inc. Common Stock were outstanding.
04/30/2025Date Issuer's Form S-3 was filed with the Securities and Exchange Commission, reporting the outstanding shares.
05/15/2025Date the Schedule 13G/A was signed and filed by the Reporting Persons.

Keywords

Allurion Technologies, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Passive Investment

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.